From: Neurofibromatosis type 2 (NF2): A clinical and molecular review
 | Number | PRE testing Mosaic inferred | PRE testing Transmission risk | POST genetic negative testing in blood Mosaic inferred | POST genetic negative testing in blood Transmission risk |
---|---|---|---|---|---|
< 20 BVS | 85 | 12% | 45% | 46% | 30% 1 in 3 |
< 20 UVS | 21 | 42% | 33% | 87% | 11% 1 in 9 |
20–29 BVS | 67 | 27% | 36% | 78% | 16% 1 in 6 |
20–29 UVS | 27 | 78% | 19% | 97% | 8% 1 in 12 |
30–39 BVS | 54 | 50% | 28% | 88% | 11% 1 in 9 |
30–39 UVS | 19 | 85% | 12% | 98% | 6% 1 in 16 |
40+ BVS | 53 | 63% | 22% | 93% | 9% 1 in 11 |
40+ UVS | 34 | 90% | 10% | 99% | 5% 1 in 20 |